TY - JOUR
T1 - Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population
T2 - Results From the PRO-CAPRI Study in the Netherlands
AU - Kuppen, Malou C P
AU - Westgeest, Hans M
AU - van den Eertwegh, Alphonsus J M
AU - Coenen, Jules L L M
AU - van Moorselaar, Reindert J A
AU - van den Berg, Pieter
AU - Geenen, Maud M
AU - Mehra, Niven
AU - Hendriks, Mathijs P
AU - Lampe, Menuhin I
AU - van de Luijtgaarden, Addy C M
AU - Peters, Frank P J
AU - Roeleveld, Ton A
AU - Smilde, Tineke J
AU - de Wit, Ronald
AU - van Oort, Inge M
AU - Gerritsen, Winald R
AU - Uyl-de Groot, Carin A
N1 - Copyright © 2019 Elsevier Inc. All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - BACKGROUND: The purpose of this study was to determine generic, cancer-specific, and prostate cancer-specific health-related quality of life (HRQoL), pain and changes over time in patients with metastatic castration-resistant prostate cancer (mCRPC) in daily practice.PATIENTS AND METHODS: PRO-CAPRI is an observational, prospective study in 10 hospitals in the Netherlands. Patients with mCRPC completed the EQ-5D, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and Brief Pain Inventory-Short Form (BPI-SF) every 3 months and European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module (EORTC QLQ-PR25) every 6 months for a maximum of 2 years. Subgroups were identified based on chemotherapy pretreatment. Outcomes were generic, cancer-specific, and prostate cancer-specific HRQoL and self-reported pain. Descriptive statistics were performed including changes over time and minimal important differences (MID) between subgroups.RESULTS: In total, 151 included patients answered 873 questionnaires. The median follow-up from the start of the study was 19.5 months, and 84% were treated with at least 1 life-prolonging agent. Overall, patients were in good clinical condition (Eatern Cooperative Oncology Group performance status 0-1 in 78%) with normal baseline hemoglobin, lactate dehydrogenase, and alkaline phosphatase. At inclusion, generic HRQoL was high with a mean EQ visual analog score of 73.2 out of 100. The lowest scores were reported on role and physical functioning (mean scores of 69 and 76 of 100, respectively), and fatigue, pain, and insomnia were the most impaired domains. These domains deteriorated in > 50% of patients.CONCLUSION: Although most patients were treated with new treatments during follow-up, mCRPC has a negative impact on HRQoL with deterioration in all domains over time, especially role and physical functioning. These domains need specific attention during follow-up to maintain HRQoL as long as possible by timely start of adequate supportive care management.
AB - BACKGROUND: The purpose of this study was to determine generic, cancer-specific, and prostate cancer-specific health-related quality of life (HRQoL), pain and changes over time in patients with metastatic castration-resistant prostate cancer (mCRPC) in daily practice.PATIENTS AND METHODS: PRO-CAPRI is an observational, prospective study in 10 hospitals in the Netherlands. Patients with mCRPC completed the EQ-5D, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and Brief Pain Inventory-Short Form (BPI-SF) every 3 months and European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module (EORTC QLQ-PR25) every 6 months for a maximum of 2 years. Subgroups were identified based on chemotherapy pretreatment. Outcomes were generic, cancer-specific, and prostate cancer-specific HRQoL and self-reported pain. Descriptive statistics were performed including changes over time and minimal important differences (MID) between subgroups.RESULTS: In total, 151 included patients answered 873 questionnaires. The median follow-up from the start of the study was 19.5 months, and 84% were treated with at least 1 life-prolonging agent. Overall, patients were in good clinical condition (Eatern Cooperative Oncology Group performance status 0-1 in 78%) with normal baseline hemoglobin, lactate dehydrogenase, and alkaline phosphatase. At inclusion, generic HRQoL was high with a mean EQ visual analog score of 73.2 out of 100. The lowest scores were reported on role and physical functioning (mean scores of 69 and 76 of 100, respectively), and fatigue, pain, and insomnia were the most impaired domains. These domains deteriorated in > 50% of patients.CONCLUSION: Although most patients were treated with new treatments during follow-up, mCRPC has a negative impact on HRQoL with deterioration in all domains over time, especially role and physical functioning. These domains need specific attention during follow-up to maintain HRQoL as long as possible by timely start of adequate supportive care management.
KW - Life-prolonging drugs
KW - Metastatic castration-resistant prostate cancer
KW - Patient-reported outcomes
KW - Real-world outcomes
KW - Registry
UR - http://www.scopus.com/inward/record.url?scp=85077011884&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.clgc.2019.11.015
DO - https://doi.org/10.1016/j.clgc.2019.11.015
M3 - Article
C2 - 31883940
SN - 1558-7673
VL - 18
SP - e233-e253
JO - Clinical genitourinary cancer
JF - Clinical genitourinary cancer
IS - 3
ER -